益生菌辅助治疗胃溃疡的随机、双盲、平行对照临床研究

注册号:

Registration number:

ChiCTR1900021456 

最近更新日期:

Date of Last Refreshed on:

2019-02-22 10:20:37 

注册时间:

Date of Registration:

2019-02-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

益生菌辅助治疗胃溃疡的随机、双盲、平行对照临床研究

Public title:

A randomized, double-blind, parallel controlled clinical study for probiotics in the treatment of gastric ulcers

注册题目简写:

English Acronym:

研究课题的正式科学名称:

益生菌辅助治疗胃溃疡的随机、双盲、平行对照临床研究

Scientific title:

A randomized, double-blind, parallel controlled clinical study for probiotics in the treatment of gastric ulcers

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

段晓燕 

研究负责人:

陈平 

Applicant:

Duan Xiaoyan 

Study leader:

Chen Ping 

申请注册联系人电话:

Applicant telephone:

+86 15849175637

研究负责人电话:

Study leader's
telephone:

+86 13848170137

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

630657625@qq.com

研究负责人电子邮件:

Study leader's E-mail:

nmgcp@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

内蒙古呼和浩特市回民区新华大街5号

研究负责人通讯地址:

内蒙古呼和浩特市回民区新华大街5号

Applicant address:

5 Xinhua Street, Huimin District, Hohhot, Inner Mongolia

Study leader's address:

5 Xinhua Street, Huimin District, Hohhot, Inner Mongolia

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

内蒙古医科大学附属医院消化内科

Applicant's institution:

Department of Gastroenterology, Affiliated hospital of Inner Mongolia medical university

研究负责人所在单位:

内蒙古医科大学附属医院消化内科

Affiliation of the Leader:

Department of Gastroenterology, Affiliated hospital of Inner Mongolia medical university

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NO.KY(2019003)

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

内蒙古医科大学附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Affiliated Hospital of Inner Mongolia Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-01-14 00:00:00

伦理委员会联系人:

张春燕、高露

Contact Name of the ethic committee:

Zhang Chunyan, Gao Lu

伦理委员会联系地址:

内蒙古呼和浩特市回民区新华大街5号

Contact Address of the ethic committee:

5 Xinhua Street, Huimin District, Hohhot, Inner Mongolia

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 0471 3451027

伦理委员会联系人邮箱:

Contact email of the ethic committee:

nyfyll@163.com

研究实施负责(组长)单位:

内蒙古医科大学附属医院消化内科

Primary sponsor:

Department of Gastroenterology, Affiliated Hospital of Inner Mongolia Medical University

研究实施负责(组长)单位地址:

内蒙古呼和浩特市回民区新华大街5号

Primary sponsor's address:

5 Xinhua Street, Huimin District, Hohhot, Inner Mongolia

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

内蒙古

市(区县):

呼和浩特市

Country:

China

Province:

Inner mongolia

City:

Hohhot

单位(医院):

内蒙古医科大学附属医院

具体地址:

回民区新华大街5号

Institution
hospital:

The Affliated Hospital Of Inner Mongolia Medical University

Address:

5 Xinhua Street, Huimin District

经费或物资来源:

内蒙古农业大学 “乳品生物技术与工程” 教育部重 点实验室

Source(s) of funding:

Key laboratory of dairy biotechnology and engineering, ministry of education, Inner Mongolia agricultural university

研究疾病:

胃溃疡  

Target disease:

Gastric Ulcer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

基础科学研究 

Study phase:

Basic Science

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本实验旨在从临床指标、免疫指标、细菌多样性变化,代谢通路及代谢物质等多方面深入研究益生菌改善胃溃疡治疗的益生作用。  

Objectives of Study:

To evaluate the probiotic effect of probiotics from clinical indicators, immune indicators, bacterial diversity, metabolic pathways and metabolic substances and to improve the treatment of gastric ulcer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

① 未按要求服用药物者;
② 不配合随访者;
③ 妊娠期和哺乳期妇女;
④ 采集标本前1个月服用影响肠道菌群药物者;
⑤ 治疗及观察期间又服用其它影响肠道菌群药物者;
⑥ 患有其它严重疾病,以及其它影响肠道菌群构成的疾病;
⑦ 反复根除幽门螺杆菌失败者;
⑧ 胃镜检查禁忌的患者。

Exclusion criteria:

1. Failing to take medicine as required;
2. Do not cooperate with the interviewer;
3. Pregnant and nursing women;
4. Taking drugs affecting intestinal flora 1 month before collection of specimens;
5. During treatment and observation and take other drugs affecting intestinal flora;
6. Suffer from other serious diseases, and other diseases that affect the composition of intestinal flora;
7. Repeatedly eradication of helicobacter pylori losers.
8. Patients who have been exposed to the taboo of gastroscopy.

研究实施时间:

Study execute time:

From 2019-03-01 00:00:00 To 2020-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-03-01 00:00:00 To 2020-03-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

80

Group:

control group

Sample size:

干预措施:

四联疗法+安慰剂

干预措施代码:

Intervention:

Quadruple therapy+placebo

Intervention code:

组别:

益生菌组

样本量:

80

Group:

Probiotic group

Sample size:

干预措施:

四联疗法+益生菌

干预措施代码:

Intervention:

Quadruple therapy+Probiotics

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

内蒙古 

市(区县):

呼和浩特 

Country:

china

Province:

Inner Mongolia

City:

Hohhot

单位(医院):

内蒙古医科大学附属医院 

单位级别:

三甲医院 

Institution
hospital:

Affiliated hospital of Inner Mongolia medical university

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

细菌多样性

指标类型:

主要指标

Outcome:

bacterial diversity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫指标

指标类型:

主要指标

Outcome:

immune index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢组学

指标类型:

主要指标

Outcome:

metabonomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

宏基因组学

指标类型:

主要指标

Outcome:

Metagenomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血清

组织:

Sample Name:

Serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

胃黏膜

组织:

Sample Name:

Gastric mucosa

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

安排入组志愿者总数200例,依次编号1-200,益生菌提供者使用excel制作随机数据对照表,将编号1-200随机平均分为益生菌组和安慰剂组。医院负责药物发放,益生菌提供单位负责记录并保管编号对应的益生菌/安慰剂信息。

Randomization Procedure (please state who generates the random number sequence and by what method):

A total of 200 volunteers were enrolled, numbered 1-200 in sequence. The probiotics supplier to make a random data comparison table using excel 2010 software, and randomly divided the numbers 1-200 into the probiotic group and the placebo group. The hospital is responsible for drug delivery, and the probiot

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲

Blinding:

Double blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

书面

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

A written

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

书面

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A written

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-02-22 10:17:16